Price controversy threatens Marathon CEO's seat on PhRMA board

Pharmaceutical Research and Manufacturers of America — the drug industry's largest lobbying group — broke its silence on the controversy surrounding the high price of Marathon Pharmaceutical's newly approved muscular dystrophy drug, reports Endpoints News.

Marathon has faced much criticism this past week for setting the list price of Emflaza at $89,000. The generic treatment has been available on foreign markets for decades and only costs about $1,200 abroad.

PhRMA on Wednesday said Marathon is "guilty of conduct unbecoming to the industry" and shared plans to launch a review of the group's membership criteria, which could put Marathon CEO Jeff Aronin's seat on PhRMA's board in jeopardy, according to the report.

"We are pleased Marathon de­cided to pause the launch of their med­i­cine to so­licit ad­di­tional input from pa­tients and other stake­hold­ers. Their re­cent ac­tions are not con­sis­tent with the mis­sion of our or­ga­ni­za­tion," PhRMA said in a statement Wednesday.

"In ad­di­tion, the lead­er­ship of the PhRMA Board of Di­rec­tors has begun a com­pre­hen­sive re­view of our mem­ber­ship cri­te­ria to en­sure we are fo­cused on rep­re­sent­ing research-based bio­phar­ma­ceu­ti­cal com­pa­nies who take sig­nif­i­cant risks to bring new treat­ments and cures to pa­tients," the statement reads.

More articles on supply chain:

Integra to buy J&J's neurosurgery business for $1B
Winter storms exacerbate blood shortage in New England
Sen. Sanders to drugmaker: 'We're going to be your worst nightmare'

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.